Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from HUM

Health-Care Stocks: CVS, Humana Make Bank of America List of Large-Caps

The health-care sector constitutes 'our favorite overweight for today's macro environment,' Bank of America analysts said.

The Street

If You Invested $1000 In Humana 20 Years Ago, Here's How Much You Would Have Today

Humana (NYSE:HUM) has outperformed the market over the past 20 years by 10.96% on an annualized basis producing an average annual return of 17.93%. Currently, Humana has a market capitalization of $54.86 billion.

Benzinga

Exxon Mobil, General Dynamics Lead Five Stocks Near Buy Points Without This Big Risk

Exxon Mobil and General Dynamics are among five stocks near buy points from strong groups that have already reported earnings.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Expert Ratings for Humana

Over the past 3 months, 6 analysts have published their opinion on Humana (NYSE:HUM) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Humana's Return On Capital Employed Overview

According to Benzinga Pro, during Q1, Humana (NYSE:HUM) earned $930.00 million, a 7253.85% increase from the preceding quarter. Humana also posted a total of $24.08 billion in sales, a 13.59% increase since Q4.

Benzinga

Humana Q1 Earnings Beats Expectations, Raises FY22 Profit Guidance

Humana Inc (NYSE:HUM) has posted Q1 adjusted sales of $24.08 billion, beating the consensus of $23.51 billion. The benefits expense ratio increased from 86.4% to 85.9%, and the operating cost ratio increased from 12% to 9.7%. Humana posted an adjusted EPS of $8.04, beating the consensus of $6.78 and $6.38 posted a…

Benzinga

Humana: Q1 Earnings Insights

Humana (NYSE:HUM) reported its Q1 earnings results on Wednesday, April 27, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Humana to Offload Substantial Stake In Kindred At Home Hospice & Personal Care Divisions

Humana Inc (NYSE:HUM) has agreed to divest a majority interest in the Hospice and Personal Care divisions of Humana's Kindred at Home (KAH Hospice) subsidiary to Clayton, Dubilier & Rice (CD&R). The divisions include patient-centered services for Hospice, Palliative, Community, and Personal Care. Humana had previously indicated its intent to divest a majority…

Benzinga

If You Invested $100 In Humana 10 Years Ago, Here's How Much You Would Have Today

Humana (NYSE:HUM) has outperformed the market over the past 10 years by 5.55% on an annualized basis producing an average annual return of 18.03%. Currently, Humana has a market capitalization of $59.08 billion.

Benzinga

UBS Upgrades Rating to Buy for Humana, Raises Price Target To $520

UBS upgraded its rating of Humana (NYSE:HUM) to Buy with a price target of $520.00, changing its price target from $486.00 to $520.00. Shares of Humana are trading up 2.2% over the last 24 hours, at $458.92 per share. A move to $520.00 would account for a 13.31% increase from…

Benzinga

This Favorable Sign Appears On Humana's Chart

If history is any guide, there may be good fortune ahead for shares of Humana (NYSE:HUM). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Benzinga

Here's How Much You Would Have Made Owning Humana Stock In The Last 5 Years

Humana (NYSE:HUM) has outperformed the market over the past 5 years by 1.74% on an annualized basis producing an average annual return of 15.84%. Currently, Humana has a market capitalization of $55.72 billion.

Benzinga

5 Undervalued Insurance Stocks to Buy Right Now

Inflation has surged to multi-year highs, so the Fed is contemplating raising interest rates aggressively this year. And an increasing interest rate environment typically translates to revenue growth for financial companies, including insurers. Thus, we think it could be wise to bet on quality insurance stocks Cigna (CI), Humana (HUM),…

StockNews.com

If You Invested $100 In This Stock 10 Years Ago, Here's How Much You Would Have Today

Humana (NYSE:HUM) has outperformed the market over the past 10 years by 5.66% on an annualized basis.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Forget Clover, Buy These 4 Healthcare Plan Stocks Instead

The pandemic-driven increase in health awareness and rising chronic diseases should drive the healthcare-plans industry’s growth. However, not all industry participants are well-positioned to gain in the near term. Clover Health (CLOV), with inconsistent financials and growth, is not expected to perform well. Therefore, fundamentally sound stocks in this space—UnitedHealth…

StockNews.com

Better Buy for 2022: Humana vs. Clover Health

The rising aging population and the increasing spending on healthcare have been driving the health insurance industry’s growth. So, Humana (HUM) and Clover (CLOV) should benefit. But which of these two stocks is a better buy now? Read more to find out.

Benzinga

Expert Ratings For Humana

Analysts have provided the following ratings for Humana (NYSE:HUM) within the last quarter:

Benzinga

Humana Q4 Bottom-Line Beats Expectations, Plans Cost Savings

Humana Inc (NYSE: HUM) posts

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Humana: Q4 Earnings Insights

Humana (NYSE:HUM) reported its Q4 earnings results on Wednesday, February 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Benzinga

Humana Earnings Preview

Humana (NYSE:HUM) is set to give its latest quarterly earnings report on Wednesday, 2022-02-02. Here's what investors need to know before the announcement. Analysts estimate that Humana will likely report an Earnings Per Share (EPS) of $1.16.

Benzinga

Death Cross Looms Over Humana Investors

If history is any guide, there may be trouble ahead for shares of Humana (NYSE:HUM). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

1 2 3 4

People

Dipanjan BanchurSince

722 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.